LAUSR

White spot syndrome virus (WSSV), a double-stranded DNA virus that infects crustaceans, is the most serious viral pathogen affecting shrimp farming worldwide. To reduce the economic losses caused by WSSV, we screened a novel coumarin derivative from a small molecule drug library, N-(4-((4-(((2-oxo-2H-chromen-7-yl)oxy)methyl)-1H-1,2,3-triazol-1-yl)sulfonyl)phenyl)acetamide (N2905), to evaluate its anti-WSSV effects in vivo. We determined that compound N2905, up to a concentration of 20 mg/L, significantly decreased the number of WSSV copies in Litopenaeus vannamei post-larvae, with a maximum inhibitory rate of > 90%, and increased the survival rate of WSSV-infected post-larvae. Pre-treatment and post-treatment assays indicated that N2905 could treat, but not prevent, WSSV infections. When WSSV was preincubated with N2905 for 1-4 h, the incidence of viral infections was significantly reduced and survival time of post-larvae extended to 120 h. A stability study of N2905 provided a reference for its practical use. Considering the antiviral stability of N2905 in culture water within 2 d, continuous N2905 exchange was performed, showing a significant decrease in viral load at 120 hours post-infection (hpi) and a 55% increase in survival of WSSV-infected post-larvae. Overall, our study demonstrated the potential of N2905 as an antiviral agent.